Abstract
This study delves into the clinical implications of cyclin-dependent kinase inhibitor 2 (CDKN2) deletion in adult T-lineage acute lymphoblastic leukemia (T-ALL). Among 241 patients included in this study, 57 had CDKN2 deletion and 184 had CDKN2 wild-type (WT), and 165 underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) and 76 did not undergo allo-HSCT. CDKN2 deletion correlated with higher white blood cell count, more high-risk diseases, and complex karyotype. The 5-year overall survival (OS) was 36.8% and 58.2% (P < 0.001), 5-year disease-free survival (DFS) was 47.1% and 59.3% (P = 0.018), and 5-year cumulative incidence of relapse (CIR) was 33.7% and 22.3% (P = 0.019) in patients with CDKN2 deletion and WT, respectively. Multivariate analysis identified CDKN2 deletion as an independent adverse prognostic factor for OS (HR 2.11, P = 0.003). In the CDKN2 deletion subgroup, landmark analysis showed that the 5-year OS was 56.7% and 19% (P = 0.002) for patients who underwent allo-HSCT and those who did not, respectively. And multivariate analysis confirmed the beneficial role of allo-HSCT in OS (HR 0.23, P < 0.001). In conclusion, CDKN2 deletion was associated with a poor prognosis in adult T-ALL, and allo-HSCT might be beneficial for this population.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author upon request.
References
Van Vlierberghe P, Ambesi-Impiombato A, De Keersmaecker K, Hadler M, Paietta E, Tallman MS, et al. Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood. 2013;122:74–82. https://doi.org/10.1182/blood-2013-03-491092.
Jabbour E, Pui CH, Kantarjian H. Progress and innovations in the management of adult acute lymphoblastic leukemia. JAMA Oncol. 2018;4:1413–20. https://doi.org/10.1001/jamaoncol.2018.1915.
La Starza R, Pierini V, Pierini T, Nofrini V, Matteucci C, Arniani S, et al. Design of a comprehensive fluorescence in situ hybridization assay for genetic classification of T-cell acute lymphoblastic leukemia. J Mol Diagn. 2020;22:629–39. https://doi.org/10.1016/j.jmoldx.2020.02.004.
Iacobucci I, Ferrari A, Lonetti A, Papayannidis C, Paoloni F, Trino S, et al. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. Clin Cancer Res. 2011;17:7413–23. https://doi.org/10.1158/1078-0432.Ccr-11-1227.
Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrison H, Jones L, et al. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol. 2012;30:3100–8. https://doi.org/10.1200/jco.2011.40.3907.
Ribera J, Morgades M, Zamora L, Montesinos P, Gómez-Seguí I, Pratcorona M, et al. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. Cancer. 2015;121:3809–17. https://doi.org/10.1002/cncr.29579.
Patel S, Mason CC, Glenn MJ, Paxton CN, South ST, Cessna MH, et al. Genomic analysis of adult B-ALL identifies potential markers of shorter survival. Leuk Res. 2017;56:44–51. https://doi.org/10.1016/j.leukres.2017.01.034.
Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114:5136–45. https://doi.org/10.1182/blood-2009-08-231217.
Grossmann V, Haferlach C, Weissmann S, Roller A, Schindela S, Poetzinger F, et al. The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL. Genes Chromosomes Cancer. 2013;52:410–22. https://doi.org/10.1002/gcc.22039.
Dirse V, Bertasiute A, Gineikiene E, Zvirblis T, Dambrauskiene R, Gerbutavicius R, et al. A population-based single nucleotide polymorphism array analysis of genomic aberrations in younger adult acute lymphoblastic leukemia patients. Genes Chromosomes Cancer. 2015;54:326–33. https://doi.org/10.1002/gcc.22246.
Jang W, Park J, Kwon A, Choi H, Kim J, Lee GD, et al. CDKN2B downregulation and other genetic characteristics in T-acute lymphoblastic leukemia. Exp Mol Med. 2019;51:1–15. https://doi.org/10.1038/s12276-018-0195-x.
Xu N, Li YL, Zhou X, Cao R, Li H, Lu QS, et al. CDKN2 gene deletion as poor prognosis predictor involved in the progression of adult B-lineage acute lymphoblastic leukemia patients. J Cancer. 2015;6:1114–20. https://doi.org/10.7150/jca.11959.
Xu N, Li YL, Li X, Zhou X, Cao R, Li H, et al. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol. 2016;9:40. https://doi.org/10.1186/s13045-016-0270-5.
Fang Q, Yuan T, Li Y, Feng J, Gong X, Li Q, et al. Prognostic significance of copy number alterations detected by multi-link probe amplification of multiple genes in adult acute lymphoblastic leukemia. Oncol Lett. 2018;15:5359–67. https://doi.org/10.3892/ol.2018.7985.
Ribera J, Zamora L, Morgades M, Vives S, Granada I, Montesinos P, et al. Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2019;58:815–9. https://doi.org/10.1002/gcc.22788.
Genescà E, Lazarenkov A, Morgades M, Berbis G, Ruíz-Xivillé N, Gómez-Marzo P, et al. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. J Hematol Oncol. 2018;11:96. https://doi.org/10.1186/s13045-018-0639-8.
Wang HP, Zhou YL, Huang X, Zhang Y, Qian JJ, Li JH, et al. CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia. Am J Hematol. 2021;96:312–9. https://doi.org/10.1002/ajh.26069.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. https://doi.org/10.1182/blood-2016-03-643544.
Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, et al. Acute lymphoblastic leukemia. J Natl Compr Canc Netw. 2012;10:858–914. https://doi.org/10.6004/jnccn.2012.0089.
A Chinese expert panel consensus on diagnosis and treatment of adult acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2012;33:789–92. https://doi.org/10.3760/cma.j.issn.0253-2727.2012.09.028.
Huang K, Dai M, Li Q, Liu N, Lin D, Wang Q, et al. Early T-cell precursor leukemia has a higher risk of induction-related infection among T-cell acute lymphoblastic leukemia in adult. Mediators Inflamm. 2020;2020:8867760. https://doi.org/10.1155/2020/8867760.
Zhang XH, Chen J, Han MZ, Huang H, Jiang EL, Jiang M, et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14:145. https://doi.org/10.1186/s13045-021-01159-2.
Qi HZ, Xu J, Yang QQ, Lin R, Wang ZX, Zhao K, et al. Effect of pediatric- versus adult-type chemotherapy regimens on outcomes of allogeneic hematopoietic stem cell transplants for adult T-cell acute lymphoblastic leukemia in first complete remission. Bone Marrow Transpl. 2022;57:1704–11. https://doi.org/10.1038/s41409-022-01796-2.
Yu S, Huang F, Fan Z, Xuan L, Nie D, Xu Y, et al. Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data. J Hematol Oncol. 2020;13:18. https://doi.org/10.1186/s13045-020-00859-5.
Yu S, Huang F, Wang Y, Xu Y, Yang T, Fan Z, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2020;34:1433–43. https://doi.org/10.1038/s41375-019-0686-3.
Wang Y, Liu QF, Lin R, Yang T, Xu YJ, Mo XD, et al. Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. Sci Bull (Beijing). 2021;66:2498–505. https://doi.org/10.1016/j.scib.2021.06.002.
Zhao XS, Liu YR, Xu LP, Wang Y, Zhang XH, Chen H, et al. Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. Am J Hematol. 2019;94:512–21. https://doi.org/10.1002/ajh.25417.
Brothman AR, Persons DL, Shaffer LG. Nomenclature evolution: changes in the ISCN from the 2005 to the 2009 edition. Cytogenet Genome Res. 2009;127:1–4. https://doi.org/10.1159/000279442.
Wang Y, Chen G, Cao R, Li J, He L, Guo X, et al. Allogeneic hematopoietic stem cell transplantation improves the prognosis of p16-deleted adult patients with acute lymphoblastic leukemia. Pharmacogenomics. 2017;18:77–84. https://doi.org/10.2217/pgs-2016-0075.
Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36:4391–400. https://doi.org/10.1002/sim.7501.
Liggett WH Jr., Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 1998;16:1197–206. https://doi.org/10.1200/jco.1998.16.3.1197.
Ling Y, Xu N, Zhao K, Han L, Zhang Q, Fan Z, et al. Allogeneic hematopoietic cell transplant overcomes the poor prognostic value of CDKN2 deletion in adult B-lineage acute lymphoblastic leukemia. Cancer Lett. 2021;510:59–66. https://doi.org/10.1016/j.canlet.2021.04.009.
Mirji G, Bhat J, Kode J, Banavali S, Sengar M, Khadke P, et al. Risk stratification of T-cell Acute Lymphoblastic Leukemia patients based on gene expression, mutations and copy number variation. Leuk Res. 2016;45:33–9. https://doi.org/10.1016/j.leukres.2016.03.002.
Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and leukemia group B study 9511. Blood. 2007;109:4164–7. https://doi.org/10.1182/blood-2006-09-045351.
Rosen O, Müller HJ, Gökbuget N, Langer W, Peter N, Schwartz S, et al. Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. Br J Haematol. 2003;123:836–41. https://doi.org/10.1046/j.1365-2141.2003.04707.x.
Jain N, Lamb AV, O’Brien S, Ravandi F, Konopleva M, Jabbour E, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127:1863–9. https://doi.org/10.1182/blood-2015-08-661702.
Patrick K, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C, et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014;166:421–4. https://doi.org/10.1111/bjh.12882.
Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123:3739–49. https://doi.org/10.1182/blood-2014-01-547695.
Toft N, Schmiegelow K, Klausen TW, Birgens H. Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998–2008. Br J Haematol. 2012;157:97–104. https://doi.org/10.1111/j.1365-2141.2011.09020.x.
Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia. 2018;32:606–15. https://doi.org/10.1038/leu.2017.265.
Xiao J, Cai Z, Wang H, Li X, Zhou B, Liu Y, et al. The clinical characteristics and prognosis of AYA and older adult ETP-ALL/LBL: a real-world multicenter study in China. Front Oncol. 2022;12:846573. https://doi.org/10.3389/fonc.2022.846573.
Luo L, Jiao Y, Yang P, Li Y, Huang WY, Ke XY, et al. Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for T lymphoblastic leukemia/lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2023;44:388–94. https://doi.org/10.3760/cma.j.issn.0253-2727.2023.05.006.
Raetz EA, Rebora P, Conter V, Schrappe M, Devidas M, Escherich G, et al. Outcome for children and young adults with T-cell ALL and induction failure in contemporary trials. J Clin Oncol. 2023;41:5025–34. https://doi.org/10.1200/jco.23.00088.
Acknowledgements
This work was supported by the National Key Research and Development Projects of China (2021YFC2500301-4, 2022YFA1105003, and 2022YFC2502600-5), the Major Project of the National Natural Science Foundation of China (No.82293634), and the National Natural Science Foundation of China (82200241).
Author information
Authors and Affiliations
Contributions
XSH wrote the initial manuscript, ZXW designed tables and figures and YTQ performed the MRD analysis. QFL and SJY designed the initial outline, contributed to the writing, and finalized the manuscript. All authors have read and approved the final manuscript. Xiaoshan Hu: Conceptualization, Methodology, Formal analysis, Writing-original draft. Zhixiang Wang: Methodology and Formal Analysis. Yuting Qin: Formal analysis. Jun Xu, Na Xu, Qiang Wang, Ren Lin, Ke Zhao, Hongsheng Zhou, Li Xuan: Resources, Data Curation. Sijian Yu and Qifa Liu: Conceptualization, writing–review and editing, visualization, supervision, and funding acquisition.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Hu, X., Wang, Z., Qin, Y. et al. Allogeneic haematopoietic stem cell transplantation might overcome the poor prognosis of adolescents and adult patients with T-lineage acute lymphoblastic leukaemia and CDKN2 deletion. Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409-024-02306-2
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41409-024-02306-2